Projects per year
Personal profile
Education
- 1985-1989 Ph.D., Graduate Institute of Medical Sciences, National Defense Medical Center
- 1976-1983 M.D., School of Medicine, National Defense Medical Center
Experience
- 2020.11- Professor, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University
- 2018.11- Deputy Director, Taipei Cancer Center, Taipei Medical University
- Director, Division of Oncology, Department of Internal Medicine, College of Medicine, Taipei Medical University
- 2018.02- Professor, International Master/Ph.D. Program in Medicine, College of Medicine, Taipei Medical University
- 2016.11-2017.10 Professor, International Master/Ph.D. Program in Medicine, College of Medicine, Taipei Medical University
- 2015.10-2019.07.31 Deputy Director, Department of Human Research, Taipei Medical University
- 2015.02- Chief, Department of Medical Affairs, Shuang Ho Hospital, Taipei Medical University
- 2014.02-2016.07 Director, Joint Clinical Research Center, Taipei Medical University
- 2010.10- Chief and Professor, Division of Hematology/Oncology, Shuang-Ho Hospital, Taipei Medical University,
- 2010.10-2015.01 Chief and Professor, Division of Internal Medicine, Shuang-Ho Hospital, Taipei Medical University, Taipei, Taiwan
- 2010.09- Professor, Graduate Institute of Clinical Medicine, Taipei Medical University
- 2010.05- Director, Division of Oncology, Tri-Service General Hospital
- 1997.08-2010.09 Chief and Professor, Division of Hematology/Oncology, Tri-Service General Hospital, National Defense Medical Center,
- 1992.08-2010.09 Attending Physician, Division of Hematology/Oncology, Tri-Service General Hospital
- 1989.07-1997.07 Associate Professor, National Defense Medical Center
- 1987-1789 Research Fellow, Department of Immunology and Biochemistry Research, Roswell Park Memorial Institute,
- 1983.08-1992.07 Resident, Chief Resident, Fellow, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center
- 1983.08-1989.06 Teaching Assistant, National Defense Medical Center
Awards
- 2019 Distinguished Clinical Trial Leader Award, Taipei Medical University
- 2008 The best 100 physicians of Taiwan
- 2005 Teacher of the year, National Defense University
- 2001 Remarkable physician of Tri-Service General Hospital
- 2000 Teacher of the year, National Defense Medical Center. September
- 1998 Decent Man, Tri-Service General Hospital
- 1997 International Who's Who of Contemporary Achievement, Hall of Fame, awarded by the American Biographical Institute
- 1996 Men of Achievement, 17th edition, published by The International Biographical Center, Cambridge, England
- 1994 Outstanding Military Physician honored by the Ministry of Defense, Taiwan, R. O. C.
- 1994-1995 Scholarship of Biomedical Science for physician awarded by Academia Sinica, Taiwan, R. O. C.
- 1993 Distinguished Youth of Taipei City
- 1992 Remarkable physician of Tri-Service General Hospital
- 1989 First class Academic Medal, awarded by Ministry of Defense, R. O. C.
- 1983 Second class Academic Medal, awarded by Ministry of Defense, R. O. C.
Research Interests
- Dr. Chao’s current researchinterests focus on clinical trials and translational studies. The clinical trials he involves are about the development of new drugs or strategies in treating cancers and hematological disorders. In translational studies, his major effort is on the development of a novel biochemical marker, i.e. tartrate-resistant acid phosphatase 5b, in the diagnosis and monitoring of metastatic bone disease of breast cancer. He also intends to define the role and search the potential usefulness of tartrate-resistant acid phosphatase 5a in macrophage-related disorders.
Fingerprint
- 1 Similar Profiles
Network
-
研究BTK/HER2信號通路在HER2陽性乳腺癌生物特性角色: 調控T細胞的效應及逆轉賀癌平抗藥性的分子機制(3/3)
8/1/21 → 7/31/22
Project: A - Government Institution › b - Ministry of Science and Technology
-
研究BTK/HER2信號通路在HER2陽性乳腺癌生物特性角色: 調控T細胞的效應及逆轉賀癌平抗藥性的分子機制(2/3)
8/1/20 → 7/1/21
Project: A - Government Institution › b - Ministry of Science and Technology
-
研究BTK/HER2信號通路在HER2陽性乳腺癌生物特性角色:調控T細胞的效應及逆轉賀癌平抗藥性的分子機制
1/1/20 → 12/31/20
Project: A - Government Institution › a - National Health Research Institutes
-
Investigating the Role of Btk/Her2 Signaling as a Therapeutic Target for Restoration of T Cell Function and Reversal of Trastuzumab Resistance in Her2+ Breast Cancer(1/3)
8/1/19 → 7/31/20
Project: A - Government Institution › b - Ministry of Science and Technology
-
雙打擊在瀰漫大B細胞淋巴瘤所扮演的角色-致病機轉與臨床特色之探討-篩選雙打擊瀰漫大B細胞淋巴瘤的新流程-根據台灣BCL6轉位之瀰漫大B細胞淋巴瘤的盛行狀況所提出的構想
1/1/19 → 12/1/19
Project: A - Government Institution › d - Ministry of Education
-
4-Acetylantroquinonol B induced DNA damage response signaling and apoptosis via suppressing CDK2/CDK4 expression in triple negative breast cancer cells
Satriyo, P. B., Su, C. M., Ong, J. R., Huang, W. C., Fong, I. H., Lin, C. C., Aryandono, T., Haryana, S. M., Deng, L., Huang, C. C., Tzeng, Y. M., Chao, T. Y., Liu, H. W. & Yeh, C. T., Jul 1 2021, In: Toxicology and Applied Pharmacology. 422, 115493.Research output: Contribution to journal › Article › peer-review
3 Citations (Scopus) -
Bruton’s tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma
Yeh, C. T., Chen, T. T., Satriyo, P. B., Wang, C. H., Wu, A. T. H., Chao, T. Y., Lee, K. Y., Hsiao, M., Wang, L. S. & Kuo, K. T., Jul 2021, In: Oncogenesis. 10, 7, 56.Research output: Contribution to journal › Article › peer-review
Open Access -
Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy
Chu, C. Y., Lee, Y. C., Hsieh, C. H., Yeh, C. T., Chao, T. Y., Chen, P. H., Lin, I. H., Hsieh, T. H., Shih, J. W., Cheng, C. H., Chang, C. C., Lin, P. S., Huang, Y. L., Chen, T. M., Yen, Y., Ann, D. K. & Kung, H. J., 2021, In: Theranostics. 11, 8, p. 3624-3641 18 p.Research output: Contribution to journal › Article › peer-review
Open Access3 Citations (Scopus) -
High-grade b-cell lymphoma (Hgbl) with myc and bcl2 and/or bcl6 rearrangements is predominantly bcl6-rearranged and bcl6-expressing in Taiwan
Tsai, C. C., Su, Y. C., Bamodu, O. A., Chen, B. J., Tsai, W. C., Cheng, W. H., Lee, C. H., Hsieh, S. M., Liu, M. L., Fang, C. L., Lin, H. T., Chen, C. L., Yeh, C. T., Lee, W. H., Ho, C. L., Lai, S. W., Tzeng, H. E., Hsieh, Y. Y., Chang, C. L., Zheng, Y. M. & 4 others, , Apr 1 2021, In: Cancers. 13, 7, 1620.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus) -
Identification of cancer hub gene signatures associated with immune-suppressive tumor microenvironment and ovatodiolide as a potential cancer immunotherapeutic agent
Chen, J. H., Wu, A. T. H., Lawal, B., Tzeng, D. T. W., Lee, J. C., Ho, C. L. & Chao, T. Y., Aug 1 2021, In: Cancers. 13, 15, 3847.Research output: Contribution to journal › Article › peer-review
Open Access9 Citations (Scopus)
Datasets
-
Potential effects of valproate and oxcarbazepine on growth velocity and bone metabolism in epileptic children- a medical center experience
Lin, C. (Contributor), Fan, H. (Contributor), Chao, T. (Contributor), Chu, D. (Contributor), Lai, C. (Contributor), Wang, C. (Contributor) & Chen, S. (Contributor), Unknown Publisher, Jan 1 2016
DOI: 10.6084/m9.figshare.c.3630170.v1, https://figshare.com/collections/Potential_effects_of_valproate_and_oxcarbazepine_on_growth_velocity_and_bone_metabolism_in_epileptic_children-_a_medical_center_experience/3630170/1
Dataset
-
Additional file 2: Figure S1. of Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448
Bamodu, O. A. (Contributor), Huang, W. (Contributor), Lee, W. (Contributor), Wu, A. T. (Contributor), Wang, L. (Contributor), Hsiao, M. (Contributor), Yeh, C. (Contributor) & Chao, T. (Contributor), Unknown Publisher, Feb 25 2016
DOI: 10.6084/m9.figshare.c.3621719_d3.v1, https://springernature.figshare.com/articles/journal_contribution/Additional_file_2_Figure_S1_of_Aberrant_KDM5B_expression_promotes_aggressive_breast_cancer_through_MALAT1_overexpression_and_downregulation_of_hsa-miR-448/4396004/1
Dataset
-
A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors
Chiang, N. (Contributor), Chao, T. (Contributor), Hsieh, R. (Contributor), Wang, C. (Contributor), Wang, Y. (Contributor), Yeh, C. (Contributor) & Chen, L. (Contributor), Unknown Publisher, Nov 21 2016
DOI: 10.6084/m9.figshare.c.3646481.v1, https://figshare.com/collections/A_phase_I_dose-escalation_study_of_PEP02_irinotecan_liposome_injection_in_combination_with_5-fluorouracil_and_leucovorin_in_advanced_solid_tumors/3646481/1
Dataset
-
Additional file 1: of A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment
Liu, K. (Contributor), Chao, T. (Contributor), Chang, J. (Contributor), Cheng, A. (Contributor), ChâAng, H. (Contributor), Kao, W. (Contributor), Wu, Y. (Contributor), Yu, W. (Contributor), Chung, T. (Contributor) & Whang-Peng, J. (Contributor), Unknown Publisher, Aug 24 2016
DOI: 10.6084/m9.figshare.c.3612833_d2.v1, https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_A_phase_I_clinical_study_of_immunotherapy_for_advanced_colorectal_cancers_using_carcinoembryonic_antigen-pulsed_dendritic_cells_mixed_with_tetanus_toxoid_and_subsequent_IL-2_treatment/4368173/1
Dataset
-
Additional file 2: of A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment
Liu, K. (Contributor), Chao, T. (Contributor), Chang, J. (Contributor), Cheng, A. (Contributor), ChâAng, H. (Contributor), Kao, W. (Contributor), Wu, Y. (Contributor), Yu, W. (Contributor), Chung, T. (Contributor) & Whang-Peng, J. (Contributor), Unknown Publisher, Aug 24 2016
DOI: 10.6084/m9.figshare.c.3612833_d1.v1, https://springernature.figshare.com/articles/dataset/Additional_file_2_of_A_phase_I_clinical_study_of_immunotherapy_for_advanced_colorectal_cancers_using_carcinoembryonic_antigen-pulsed_dendritic_cells_mixed_with_tetanus_toxoid_and_subsequent_IL-2_treatment/4368140/1
Dataset